Last reviewed · How we verify

Placebo for Cannabis

University of Colorado, Denver · Phase 3 active Small molecule

A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the patient's expectation and psychological response.

A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the patient's expectation and psychological response. Used for Control arm in cannabis efficacy and safety trial.

At a glance

Generic namePlacebo for Cannabis
SponsorUniversity of Colorado, Denver
ModalitySmall molecule
Therapeutic areaNeurology/Psychiatry
PhasePhase 3

Mechanism of action

Placebos are inert substances used as controls in clinical trials to measure the effect of patient expectation, belief, and the therapeutic context independent of any pharmacological action. In this Phase 3 trial for cannabis, the placebo serves as a comparator to isolate the true pharmacological effects of cannabis from placebo response effects. The placebo effect can involve neurobiological mechanisms including endogenous opioid release, dopamine activation, and other central nervous system changes triggered by expectation.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: